Intravenous insulin treatment for AD patients had similar results with non-APOE4 carriers having increased memory facilitation and decreased APP levels, while APOE4 carriers showed no cognitive differences, and increased APP levels [87]. This evidence concerns the gene APP and Alzheimer disease.